JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266615

Human TAGLN2 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

TAGLN2 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2.

View Alternative Names

CDABP0035, HA1756, KIAA0120, SM22-alpha homolog, TAGL2_HUMAN, Transgelin-2, epididymis tissue protein Li 7e

2 Images
Sanger Sequencing - Human TAGLN2 knockout HEK-293T cell line (AB266615)
  • Sanger seq

Unknown

Sanger Sequencing - Human TAGLN2 knockout HEK-293T cell line (AB266615)

Allele-1 : 1 bp deletion in exon 2

Sanger Sequencing - Human TAGLN2 knockout HEK-293T cell line (AB266615)
  • Sanger seq

Unknown

Sanger Sequencing - Human TAGLN2 knockout HEK-293T cell line (AB266615)

Allele-2 : 1 bp insertion in exon 2.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266615-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266615 Human TAGLN2 knockout HEK-293T cell line", "number":"AB266615-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266615-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266615 Human TAGLN2 knockout HEK-293T cell line", "number":"AB266615-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
TAGLN2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TAGLN2 also known as Transgelin-2 is a protein with a mass of approximately 22 kDa. It functions as an actin-binding protein playing a role in the stabilization of actin filaments. This activity is important for the regulation of cellular shape and motility. TAGLN2 expression is present in various tissues with high levels seen in smooth muscle cells. Additionally its expression in non-muscle tissues indicates a versatile function in the cytoskeletal dynamics of different cell types.
Biological function summary

The protein aids in maintaining cell structure and facilitates cell movement and adhesion. TAGLN2 is a monomer and does not form complexes but interacts closely with actin to regulate cytoskeletal processes. It acts as a modulator of actin filament organization which impacts cellular responses. The protein supports processes such as wound healing and embryonic development by influencing the migration and invasion of cells.

Pathways

TAGLN2 influences cellular mechanisms related to the actin cytoskeleton structure and dynamics. It plays a role in the Rho signaling pathway which is essential for cytoskeletal rearrangement and maintaining cellular tension. The protein associates with RhoA a small GTPase which is involved in mediating various functions including contractility and motility. Through RhoA TAGLN2 impacts cell morphology and stress fiber formation.

Abnormal expression or function of TAGLN2 connects with different pathological conditions like cancer and cardiovascular diseases. Overexpression of TAGLN2 has been linked to enhanced tumor cell migration and metastasis making it relevant in cancer progression studies. The protein also associates with TRPC6 in cardiovascular disorders where dysregulation may lead to altered vascular function contributing to the disease state. Insights into TAGLN2 can aid in developing therapeutic strategies for managing these conditions.

Quality control

STR analysis

D5S818, TH01, D16S539, TPOX, CSF1PO, D13S317, D7S820

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com